Tag Archives: biosimilars

FDA Gets More Funding, IPAB Gets Less

After two years in budget limbo, Congress finally enacted federal spending legislation for fiscal year 2014 last week, just before the latest funding extension ran out. In this period of ever-tighter government outlays, the Food and Drug Administration did fairly well in gaining additional funds, along with user fee revenues that had been put on […]
Posted in FDA, healthcare, Legal, Regulatory, Safety | Also tagged , , , , , , , | Leave a comment

Global Biosimilars Market to Reach $2.4 Billion in 2013

By Adeline Siew, Editor, Pharmaceutical Technology Europe. The global market for biosimilar drugs has been forecasted to be worth $2.445 billion this year, according to a new report by British market research specialist Visiongain. The growth represents a 20% increase from last year and accounts for approximately 2% of the overall biologics market. Moreover, the […]
Posted in Biotech, Global, Guest Blog, R&D | Also tagged , , | Leave a comment

U.S. Biosimilars Under Threat?

by D’vorah Graeser, Graeser Associates International While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for […]
Posted in Biotech, FDA, Guest Blog, IP, Legal, Regulatory, Strategy, Technology | Also tagged , , | 1 Comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare […]
Posted in Agency Insight, Biotech, Emerging Markets, Europe, Strategy | Also tagged , | 2 Comments

Innovators: Take a Leaf from the Generic Industry Book

No-one can accuse the European generic industry of indolence. It supplies huge quantities of medicines to European healthcare suppliers — its volume is estimated at around a half of the market. It is accounting for a growing share of marketing authorization applications in Europe. And its industry association, the EGA, has turned it from being […]
Posted in Europe, healthcare, Regulatory | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta